Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.

@article{Schuessler2014AutologousTT,
  title={Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.},
  author={Andrea Schuessler and Corey Smith and Leone Beagley and Glen M Boyle and Sweera Rehan and Katherine M. Matthews and Linda Jones and Tania Crough and Vijayendra Dasari and Kerenaftali Klein and A. Smalley and Hamish Alexander and David G. Walker and Rajiv Khanna},
  journal={Cancer research},
  year={2014},
  volume={74 13},
  pages={
          3466-76
        }
}
Glioblastoma multiforme (GBM) is one of the most aggressive human brain malignancies. Even with optimal treatment, median survival is less than 6 months for patients with recurrent GBM. Immune-based therapies have the potential to improve patient outcome by supplementing standard treatment. Expression of human cytomegalovirus (CMV) antigens in GBM tissues provides the unique opportunity to target viral antigens for GBM therapy. Here, we report findings of a formal clinical assessment of safety… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 75 CITATIONS, ESTIMATED 61% COVERAGE

Adoptive immunotherapy

VIEW 4 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 13 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation

KM Hertoghs, PD Moerland, +3 authors PJ van de Berg
  • J Clin Invest. 2010;120:4077-90. Research. on May
  • 2014
VIEW 1 EXCERPT

Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival.

  • Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • 2013
VIEW 2 EXCERPTS